End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.86 CNY | -0.18% | +1.41% | +9.54% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.34 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.54% | 6.12B | C | ||
-32.59% | 15.18B | B- | ||
-31.97% | 10.1B | B | ||
-11.41% | 5.97B | C+ | ||
-30.42% | 5.65B | B | ||
-0.88% | 4.71B | D- | ||
+51.58% | 4.26B | - | C | |
-12.22% | 3.58B | B | ||
-16.75% | 3.26B | C- | ||
-6.93% | 3.07B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603939 Stock
- Ratings Yifeng Pharmacy Chain Co., Ltd.